[
  {
    "ts": null,
    "headline": "Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness. About 255 participants will be included in the randomized, double-blind […]",
    "url": "https://finnhub.io/api/news?id=ead721171471cd8070bcc12bb663b8afd49c83bdbaa0a947f175adb45797394a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750656972,
      "headline": "Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.",
      "id": 135482453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children aged 2 to 16 with Friedreich ataxia (FA), a rare neurological illness. About 255 participants will be included in the randomized, double-blind […]",
      "url": "https://finnhub.io/api/news?id=ead721171471cd8070bcc12bb663b8afd49c83bdbaa0a947f175adb45797394a"
    }
  }
]